Comparison of plasma ctDNA and tissue/cytology-based techniques for the detection of EGFR mutation status in advanced NSCLC: Spanish data subset from ASSESS.

about

Comparison of plasma ctDNA and tissue/cytology-based techniques for the detection of EGFR mutation status in advanced NSCLC: Spanish data subset from ASSESS.

Item

http://www.wikidata.org/entity/Q54117313

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Comparison of plasma ctDNA and ...... anish data subset from ASSESS.

@en

Comparison of plasma ctDNA and ...... anish data subset from ASSESS.

@nl

type

Item

label

Comparison of plasma ctDNA and ...... anish data subset from ASSESS.

@en

Comparison of plasma ctDNA and ...... anish data subset from ASSESS.

@nl

prefLabel

Comparison of plasma ctDNA and ...... anish data subset from ASSESS.

@en

Comparison of plasma ctDNA and ...... anish data subset from ASSESS.

@nl

P1476

Comparison of plasma ctDNA and ...... anish data subset from ASSESS.

@en

P2093

A Paredes-Lario

http://www.w3.org/2001/XMLSchema#string

C García-Girón

http://www.w3.org/2001/XMLSchema#string

G López-Vivanco

http://www.w3.org/2001/XMLSchema#string

G Márquez

http://www.w3.org/2001/XMLSchema#string

M Constenla

http://www.w3.org/2001/XMLSchema#string

M Reck

http://www.w3.org/2001/XMLSchema#string

P Diz-Tain

http://www.w3.org/2001/XMLSchema#string

R García-Gomez

http://www.w3.org/2001/XMLSchema#string

P2860

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

Liquid biopsies: genotyping circulating tumor DNA

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

The new World Health Organization classification of lung tumours.

A comparison of EGFR mutation testing methods in lung carcinoma: direct sequencing, real-time PCR and immunohistochemistry

P2888

s12094-018-1855-y

P304

1261-1267

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12094-018-1855-Y

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Edurne Arriola

P577

2018-04-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29623586

http://www.w3.org/2001/XMLSchema#string

P932

6153859

http://www.w3.org/2001/XMLSchema#string